London, UK – [Insert Date] – AstraZeneca, through its rare disease arm Alexion Pharmaceuticals, faces a significant hurdle in its quest to bring efzimfotase alfa to patients suffering from hypophosphatasia (HPP). The company announced that its enzyme replacement therapy (ERT) candidate failed to meet the primary endpoint in the pivotal Phase III HICKORY study. Despite this disappointment, AstraZeneca has expressed a strong commitment to continuing its development efforts, citing promising subgroup data and the unmet need in this rare and debilitating genetic condition.
Hypophosphatasia is a severe, inherited metabolic disorder characterized by defective bone mineralization, leading to a range of skeletal abnormalities, dental problems, and in severe cases, premature death. The disease stems from mutations in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme crucial for the breakdown of certain substances that inhibit bone and tooth mineralization. This deficiency results in an accumulation of inorganic pyrophosphate (PPi), which interferes with the deposition of calcium and phosphate, essential building blocks for healthy bones and teeth.
The HICKORY study, a randomized, double-blind, placebo-controlled trial (NCT06079281), evaluated the efficacy and safety of efzimfotase alfa in adults and adolescents diagnosed with HPP who had not previously received Alexion’s marketed ERT, Strensiq (asfotase alfa). The primary endpoint of the study was the change from baseline in the six-minute walk test (6MWT) after 25 weeks of treatment. This widely used functional assessment measures the distance a patient can walk in six minutes, serving as a proxy for cardiorespiratory fitness and lower limb function.
Chronology of Development and Trial Results
AstraZeneca’s journey with efzimfotase alfa represents a significant investment in addressing the complex challenges of rare diseases. The development of this ERT candidate aimed to offer a novel therapeutic approach for HPP, building upon the understanding of TNSALP deficiency.
The Phase III HICKORY trial was designed to be the cornerstone of efzimfotase alfa’s regulatory submission, intended to provide robust evidence of its clinical benefit. Patients were enrolled with the expectation that efzimfotase alfa would demonstrate a statistically significant improvement in their ability to walk compared to those receiving a placebo.
However, the results revealed a complex picture. While efzimfotase alfa demonstrated a numerical improvement of 17.05 meters in the 6MWT from baseline after 25 weeks of treatment, this improvement was not statistically significant when compared to the placebo group. This outcome means that the observed difference between the efzimfotase alfa and placebo arms did not reach the predefined threshold for statistical significance, thus failing to meet the study’s primary objective.
AstraZeneca’s statement acknowledged that the placebo group in the HICKORY trial exhibited "better-than-expected" improvements in the 6MWT. This unexpected performance from the placebo arm may have contributed to the difficulty in demonstrating a statistically significant difference, even with a numerical benefit observed in the treatment group. Such scenarios are not uncommon in clinical trials, particularly in rare diseases where patient populations are smaller and more variable.
Supporting Data and Promising Subgroup Analyses
Despite the primary endpoint miss, AstraZeneca has highlighted several aspects of the HICKORY study that provide a basis for optimism and continued development. The company emphasized the results of a post-hoc analysis that revealed significant findings regarding clinically meaningful improvements in patients treated with efzimfotase alfa.
This analysis focused on the achievement of a minimum clinically important difference (MCID) in the 6MWT. MCID is a concept used in clinical research to define the smallest change in a treatment outcome that patients perceive as beneficial. In the HICKORY study, a 30% improvement from baseline in the 6MWT was considered a significant clinical threshold. The post-hoc analysis indicated that 45.2% of patients treated with efzimfotase alfa achieved this MCID, compared to only a 30% rate in the placebo arm. This represents a 2.5-fold higher likelihood of achieving a clinically meaningful improvement in walking distance for patients receiving efzimfotase alfa.
The study defined MCID in the 6MWT as improvements of 31.1 meters for adults and 43 meters for adolescents. The finding that a substantial proportion of patients on efzimfotase alfa reached these meaningful thresholds, even if not statistically significant against placebo in the primary endpoint, suggests a potential for tangible patient benefit.
Furthermore, efzimfotase alfa demonstrated statistically significant improvements in patient-reported outcomes, specifically in reducing levels of fatigue. Fatigue is a common and debilitating symptom for individuals with HPP, impacting their quality of life and ability to engage in daily activities. The positive impact on fatigue is a crucial secondary finding that could contribute to the overall therapeutic value of efzimfotase alfa.
In addition to the MCID analysis and fatigue improvements, the study also observed a nominally significant 35.6-meter benefit in 6MWT values versus placebo when analyzing a combination of prespecified subgroups of patients with pediatric-onset HPP. While "nominally significant" indicates a statistical finding that has not been adjusted for multiple comparisons and thus requires cautious interpretation, it still points to a potential treatment effect within this specific patient population.
For adults with adult-onset HPP, a prespecified subgroup analysis revealed clinically meaningful improvements in the Lower Extremity Functional Scale (LEFS), another measure of lower limb function, and nominally significant and clinically meaningful improvements in the FACIT-Fatigue scale. These findings suggest that efzimfotase alfa may offer specific benefits to certain patient groups within the broader HPP population.
Official Responses and Strategic Outlook
AstraZeneca’s leadership has articulated a clear commitment to continuing the development of efzimfotase alfa, despite the challenges posed by the HICKORY study’s primary endpoint miss. Gianluca Pirozzi, Senior Vice President and Head of Development, Regulatory and Safety at AstraZeneca’s rare disease division, emphasized the company’s dedication to bringing the drug to patients.
"Despite the outcome of the primary endpoint in the HICKORY study, we remain committed to our efforts to bring efzimfotase alfa to patients with hypophosphatasia," Pirozzi stated. He underscored the rarity and severity of HPP and the limited treatment options currently available, reinforcing the imperative to explore all potential avenues for therapeutic advancement.
The company’s strategy appears to be focused on leveraging the promising subgroup data and the drug’s potential to address specific unmet needs within the HPP patient community. This approach is not uncommon in the development of treatments for rare diseases, where achieving statistical significance in a heterogeneous population can be challenging. The emphasis on clinically meaningful improvements, even if not statistically significant at the primary endpoint, reflects a patient-centric view of drug development.
AstraZeneca’s decision to press forward with efzimfotase alfa also speaks to the broader market landscape for HPP treatments. Currently, Strensiq (asfotase alfa) is the only drug approved in the United States for HPP. Analysts from GlobalData, the parent company of Clinical Trials Arena, project that Strensiq’s sales are expected to peak around $2 billion in 2027 but are forecast to decline by over 35% by 2032. This projected market trajectory suggests an opportunity for new entrants or complementary therapies that can offer distinct advantages or address different patient needs.
Implications for Patients and the Rare Disease Landscape
The continued pursuit of efzimfotase alfa by AstraZeneca carries significant implications for patients living with hypophosphatasia. The disease imposes a substantial burden on individuals and their families, impacting their physical function, bone health, and overall quality of life. The limited therapeutic landscape means that many patients have few options for managing their condition, making the development of new treatments a critical priority.
The promising findings in subgroups and the improvements in fatigue, even in the context of a missed primary endpoint, offer a glimmer of hope for patients who may benefit from efzimfotase alfa. The focus on MCID suggests that the drug could provide a tangible improvement in daily functioning for a subset of individuals with HPP.
Beyond the immediate impact on HPP patients, AstraZeneca’s stance on efzimfotase alfa highlights a broader trend in rare disease drug development: the willingness of pharmaceutical companies to navigate complex clinical trial outcomes and pursue potentially valuable therapies based on nuanced data. This approach is essential for addressing the unmet needs of populations with rare and often devastating conditions.
The competitive landscape for HPP treatments is also evolving. The recent acquisition of Alesta Therapeutics and its candidate ALE1 by BioMarin for $490 million in August 2026 signifies growing interest and investment in the HPP market. ALE1, an inorganic pyrophosphate-lowering therapy, is currently in early-stage clinical evaluation. This increased competition underscores the potential for innovation and the ongoing efforts to discover and develop more effective treatments for HPP.
Ultimately, the path forward for efzimfotase alfa will likely involve further investigation into its efficacy and safety, potentially through additional clinical studies or refined analyses of existing data. AstraZeneca’s commitment suggests that the company believes the potential benefits of efzimfotase alfa, particularly for specific patient populations, warrant continued exploration. The ongoing efforts in the HPP space, driven by companies like AstraZeneca and BioMarin, offer a testament to the progress being made in rare disease research and the unwavering pursuit of solutions for patients facing challenging medical conditions. The coming years will be critical in determining whether efzimfotase alfa can ultimately find its place as a valuable therapeutic option for individuals living with hypophosphatasia.
About the Author
